Curative Biosciences

Curative Biosciences FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Curative Biosciences (CBDX) as of Oct 30, 2026 is 24.06 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 1.75 % — a change of 1,274.70% (higher).

FCF Conversion

24.06 %

YoY

1,274.70%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Curative Biosciences is 2017 24.06 % . FCF Conversion Rate (FCF/EBITDA) of Curative Biosciences was 2016 1.75 % . It decreases by 1,274.70% higher compared to the previous year.

The Curative Biosciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
0.48 USD
Jan 1, 2015
1.94 USD
Jan 1, 2016
1.75 USD
Jan 1, 2017
24.06 USD
The Curative Biosciences FCF Conversion history
YEARFCF ConversionYoY
24.06 %+1,274.70%
1.75 %-9.79%
1.94 %+303.36%
0.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curative Biosciences Stock analysis

What does Curative Biosciences do? Curative Biosciences Inc is a biotechnology company specializing in the development of innovative therapies for serious diseases. The company was founded in 2011 by a group of experienced scientists, medical experts, and entrepreneurs and is based in San Francisco, California. History Curative Biosciences Inc aims to develop groundbreaking therapies for diseases that currently have no effective treatment options. The company has had an impressive track record in recent years, as evidenced by numerous awards and recognition from reputable institutions and media. Business Model Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. The company conducts intensive research to identify and develop promising drug candidates. Divisions Curative Biosciences Inc has focused on several divisions to offer a wide range of innovative therapy options: - Oncology: Curative Biosciences Inc has developed a portfolio of drug candidates that specifically target malignant tumors without damaging healthy tissue. - Autoimmune diseases: The company has also developed some promising drug candidates for autoimmune diseases that regulate the immune system and reduce the risk of side effects and complications. - Neurodegenerative diseases: Curative Biosciences Inc is intensively working on the development of therapies against neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Products The company has already developed several promising products that are currently in clinical trials. Here are some examples: - CB-01: A drug candidate specifically developed to target aggressive tumors such as lung cancer, pancreatic cancer, and leukemia. - CB-02: A drug candidate that regulates the immune system and could be used in the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. - CB-03: A promising drug candidate against Alzheimer's disease that reduces β-amyloid proteins in the brain and could slow down the progression of the disease. Summary Curative Biosciences Inc is an emerging biotechnology company specializing in the development of innovative therapies for serious diseases. The company conducts intensive research and has already developed several promising drug candidates that are currently in clinical trials. Curative Biosciences Inc has developed a unique business model based on the combination of basic research, product development, and marketing. Curative Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curative Biosciences stock

FCF Conversion Rate (FCF/EBITDA) of Curative Biosciences is 24.06 % in 2017.

FCF Conversion Rate (FCF/EBITDA) of Curative Biosciences changed from 1.75 % to 24.06 %, representing a 1,274.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Curative Biosciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Curative Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curative Biosciences

All Key Metrics — Curative Biosciences